First Mercantile Trust Co. reduced its stake in Core Laboratories N.V. (NYSE:CLB) by 9.7% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,955 shares of the oil and gas company’s stock after selling 535 shares during the period. First Mercantile Trust Co.’s holdings in Core Laboratories N.V. were worth $502,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. UBS Asset Management Americas Inc. boosted its stake in shares of Core Laboratories N.V. by 0.5% in the fourth quarter. UBS Asset Management Americas Inc. now owns 114,731 shares of the oil and gas company’s stock valued at $13,772,000 after buying an additional 556 shares in the last quarter. Creative Planning boosted its stake in shares of Core Laboratories N.V. by 1.9% in the first quarter. Creative Planning now owns 1,730 shares of the oil and gas company’s stock valued at $200,000 after buying an additional 33 shares in the last quarter. Gulf International Bank UK Ltd boosted its stake in shares of Core Laboratories N.V. by 3.1% in the first quarter. Gulf International Bank UK Ltd now owns 13,449 shares of the oil and gas company’s stock valued at $1,553,000 after buying an additional 400 shares in the last quarter. Bank of Montreal Can boosted its stake in shares of Core Laboratories N.V. by 462.4% in the first quarter. Bank of Montreal Can now owns 163,920 shares of the oil and gas company’s stock valued at $18,937,000 after buying an additional 134,773 shares in the last quarter. Finally, Atria Investments LLC boosted its stake in shares of Core Laboratories N.V. by 11.2% in the first quarter. Atria Investments LLC now owns 3,839 shares of the oil and gas company’s stock valued at $443,000 after buying an additional 388 shares in the last quarter.

Core Laboratories N.V. (NYSE CLB) opened at 89.65 on Wednesday. Core Laboratories N.V. has a 52-week low of $89.64 and a 52-week high of $125.83. The firm has a 50-day moving average of $101.01 and a 200 day moving average of $108.24. The company has a market capitalization of $3.96 billion, a P/E ratio of 55.00 and a beta of 1.60.

Core Laboratories N.V. (NYSE:CLB) last released its quarterly earnings data on Monday, July 24th. The oil and gas company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.51 by $0.01. The business had revenue of $163.90 million for the quarter, compared to the consensus estimate of $168.23 million. Core Laboratories N.V. had a net margin of 11.80% and a return on equity of 49.29%. The business’s revenue for the quarter was up 10.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.35 EPS. Equities analysts predict that Core Laboratories N.V. will post $2.09 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 14th. Stockholders of record on Monday, July 17th were issued a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 2.45%. The ex-dividend date was Thursday, July 13th. Core Laboratories N.V.’s dividend payout ratio (DPR) is currently 134.15%.

TRADEMARK VIOLATION WARNING: This piece was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/first-mercantile-trust-co-lowers-stake-in-core-laboratories-n-v-clb/1493929.html.

CLB has been the topic of several research reports. Loop Capital upgraded shares of Core Laboratories N.V. from a “hold” rating to a “buy” rating and raised their target price for the stock from $125.00 to $130.00 in a report on Friday, April 21st. Zacks Investment Research upgraded shares of Core Laboratories N.V. from a “sell” rating to a “hold” rating in a report on Friday, April 21st. ABN Amro upgraded shares of Core Laboratories N.V. to a “hold” rating in a report on Friday, April 21st. Scotiabank set a $136.00 target price on shares of Core Laboratories N.V. and gave the stock a “hold” rating in a report on Saturday, April 22nd. Finally, ValuEngine cut shares of Core Laboratories N.V. from a “hold” rating to a “sell” rating in a report on Tuesday, June 6th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $117.17.

About Core Laboratories N.V.

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories N.V. (NYSE:CLB).

Institutional Ownership by Quarter for Core Laboratories N.V. (NYSE:CLB)

Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.